JOSEPH L HERRING
CIK 1229873 · CEO of Covance Drug Division · last filed 2026-03-09
JOSEPH L HERRING is a CEO of Covance Drug Division who has filed 56 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for HSIC, was dated Mar 9, 2026. Across all open-market trades the lifetime net is −$56.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$5.50M
4
56
-$56.74M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HSIC | Director | 31,859 | $81.25 | $2.59M | $127.1K | 14 | 2026-03-09 |
| TMH | Director | 2,982 | $49.12 | $146.5K | $0 | 4 | 2016-05-24 |
| LH | CEO of Covance Drug Division | 10,404 | $266.16 | $2.77M | -$4.49M | 3 | 2015-08-04 |
| COVANCE INC (CVD) Delisted | Chairman and CEO | 175,643 | — | — | -$52.38M | 34 | 2014-12-19 |
Recent Filings
56 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-09 | HSIC | Grant (A) | +2,577 | $0 | EDGAR |
| 2025-03-06 | HSIC | Grant (A) | +2,844 | $0 | EDGAR |
| 2024-03-05 | HSIC | Grant (A) | +2,604 | $0 | EDGAR |
| 2023-03-03 | HSIC | Grant (A) | +2,250 | $0 | EDGAR |
| 2022-03-18 | HSIC | Grant (A) | +2,028 | $0 | EDGAR |
| 2021-03-05 | HSIC | Grant (A) | +2,790 | $0 | EDGAR |
| 2020-03-05 | HSIC | Grant (A) | +2,889 | $0 | EDGAR |
| 2019-03-06 | HSIC | Grant (A) | +2,972 | $0 | EDGAR |
| 2018-03-06 | HSIC | Grant (A) | +2,843 | $0 | EDGAR |
| 2017-03-27 | HSIC | Buy (P) | +267 | $41.2K | EDGAR |